Original articleTwelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension
Section snippets
Study Design
This prospective, randomized, multicenter (32 sites in the United States), double-masked, parallel-group, phase 3 study compared bimatoprost 0.01%, bimatoprost 0.0125%, and bimatoprost 0.03% in patients with glaucoma or OHT. The investigators and sites that took part in the study are listed in the Acknowledgments. The study was conducted in accordance with applicable Good Clinical Practice regulations and guidelines.
Study Population
Eligible patients were at least 18 years of age with a diagnosis of OHT,
Patient Characteristics and Disposition
A total of 561 patients were enrolled in the 3 study groups. Patient demographics and clinical characteristics at baseline generally were similar among the treatment groups (Table 1). Patients ranged in age from 23 to 94 years (mean, 63.5 years). Approximately 73% of the patients were white, 14% were black, 57% were female, and 72% required washout of previous ocular hypotensive medication, most commonly a prostaglandin (36%) or bimatoprost (15%). Slightly more than half of the patients (53%)
Discussion
In this study, IOP-lowering efficacy was maintained and tolerability was improved when the concentration of bimatoprost was reduced from 0.03% to 0.01% (or 0.0125%) in the test formulations. All 3 bimatoprost formulations were well accepted by patients and physicians, and all were well tolerated, but the incidence of treatment-related adverse events was statistically and clinically significantly reduced in the bimatoprost 0.01% and 0.0125% groups compared with the bimatoprost 0.03% group, and
L. Jay Katz, MD, FACS, is a Professor of Ophthalmology at Jefferson Medical College and Director of the Glaucoma Service at Wills Eye Institute, Philadelphia, Pennsylvania. He received his MD degree from Yale University Medical School and completed an internship in Internal Medicine at the University of Virginia, a residency in Ophthalmology at Yale, and a Fellowship in Glaucoma at Wills Eye Hospital. He received the 2002 AAO Senior Achievement Award. His research interests include glaucoma.
References (30)
- et al.
Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension
Surv Ophthalmol
(2004) - et al.
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Am J Ophthalmol
(2003) - et al.
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials
Ophthalmology
(2005) - et al.
A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension
Surv Ophthalmol
(2004) - et al.
Latanoprost, a prostaglandin analog, for glaucoma therapyEfficacy and safety after 1 year of treatment in 198 patients
Ophthalmology
(1996) - et al.
Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study
Am J Ophthalmol
(2004) - et al.
Bimatoprost: a novel antiglaucoma agent
Cardiovasc Drug Rev
(2004) - et al.
Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension
Arch Ophthalmol
(2002) - et al.
Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4
Br J Ophthalmol
(2008) - et al.
Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials
J Glaucoma
(2008)
Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials
Adv Ther
Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma
Curr Med Res Opin
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Br J Ophthalmol
A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy
Curr Med Res Opin
Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand
J Med Assoc Thai
Cited by (0)
L. Jay Katz, MD, FACS, is a Professor of Ophthalmology at Jefferson Medical College and Director of the Glaucoma Service at Wills Eye Institute, Philadelphia, Pennsylvania. He received his MD degree from Yale University Medical School and completed an internship in Internal Medicine at the University of Virginia, a residency in Ophthalmology at Yale, and a Fellowship in Glaucoma at Wills Eye Hospital. He received the 2002 AAO Senior Achievement Award. His research interests include glaucoma.